GE launches cancer assay with eye on companion Dx
GE著眼于腫瘤的伴隨診斷
GE Healthcare ($GE) has been steadily building up its diagnostics offerings over the past three years, and now the company is launching a sequencing assay targeting solid tumors in clinical trials.
GE醫(yī)療已經(jīng)在過(guò)去3年中進(jìn)軍診斷行業(yè)，并奠定了堅(jiān)實(shí)的基礎(chǔ)，現(xiàn)在GE再次發(fā)力，為腫瘤的臨床試驗(yàn)提供DNA測(cè)序檢測(cè)。
The assay, sold through GE's Clarient Diagnostic Services arm, is designed to help developers target patient populations and lead to companion deals down the road. The test is the first GE has launched since buying up the research lab SeqWright last year, and folding that company's capabilities into Clarient cleared the way for GE to develop cutting-edge diagnostics, the company said.
這項(xiàng)檢測(cè)，由GE的診斷事業(yè)部 - Clarient診斷來(lái)提供，目的在于為制藥研發(fā)公司提供特定的病人群，并沿著藥物研發(fā)的途徑，拓展下游業(yè)務(wù)。這項(xiàng)檢測(cè)是GE去年收購(gòu)了SeqWright實(shí)驗(yàn)室之后，第一次發(fā)力，并整合到GE的診斷事業(yè)部，從而為GE提供最前沿的診斷業(yè)務(wù)。
Its latest offering targets the 26 most common oncogenes and tumor-suppressor genes, present in lung cancer, breast cancer, colon cancer and melanoma. More and more drugmakers are developing targeted therapies for cancer, Clarient said, and focusing on the most relevant and actionable genes will help the company serve a growing need in the industry, all part of GE's $1 billion investment in oncology R&D.
最新的檢測(cè)圍繞26個(gè)常見(jiàn)的腫瘤基因和抑癌基因，尤其是在肺癌、乳腺癌、結(jié)直腸癌和黑色素瘤領(lǐng)域。越來(lái)越多的制藥公司正在開(kāi)發(fā)腫瘤靶向治療藥物， Clarinet說(shuō)，GE公司聚焦于最相關(guān)、最有意義的基因?qū)椭鶪E公司進(jìn)軍制藥行業(yè)，目前GE已經(jīng)在腫瘤研發(fā)領(lǐng)域投資了10億美元。
"When GE Healthcare acquired SeqWright last year, one goal was to add incremental value to our existing pharmaceutical and biotechnology partnerships throughout their drug development and companion diagnostic development efforts," Clarient CEO Carrie Eglinton-Manner said in a statement. "Availability of this next-generation assay is realization of that goal."
“去年GE收購(gòu)SeqWright公司，目的之一就是為現(xiàn)在的制藥、生物制藥公司，提供藥物研發(fā)的幫助，以及伴隨診斷”，Clariet公司CEO說(shuō)， 新一代測(cè)序技術(shù)完成能實(shí)現(xiàn)之一目標(biāo)。
GE bought Clarient for $587 million back in 2010 and has gradually added to its diagnostic heft ever since, most recently striking a deal with Insight Genetics to develop a molecular diagnostic for ALK gene mutations, which are tied to lung and other cancers.
GE公司2010年以5.87億美元收購(gòu)了Clarient公司，此后不斷增強(qiáng)其診斷事業(yè)部，最近與Insight公司達(dá)成一項(xiàng)協(xié)議，開(kāi)發(fā)ALK基因突變的分子診斷，該基因與肺癌和其他腫瘤治療密切相關(guān)。
